Telitacicept Treatment Refractory Lupus Nephritis: A Case Report

Area of Science:

• Nephrology
• Rheumatology
• Immunology

Background:

• Refractory lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), often leading to kidney failure.
• Biological agents are increasingly used for SLE due to their specificity and favorable side-effect profiles.
• Limited data exist on the efficacy of telitacicept for refractory LN.

Observation:

• A case study involving a 25-year-old female patient with refractory lupus nephritis is presented.
• The patient developed Pneumocystis jirovecii pneumonia during conventional multi-targeted therapy.
• Treatment with telitacicept in combination with low-dose mycophenolate mofetil (MMF) was initiated.

Findings:

• Telitacicept combined with low-dose MMF demonstrated rapid relief of proteinuria in the patient.
• The treatment regimen was well-tolerated, with no significant adverse events reported.
• This suggests a positive therapeutic effect of telitacicept in refractory LN.

Implications:

• Telitacicept may be a viable and safe treatment option for refractory lupus nephritis.
• Combination therapy with low-dose MMF warrants further investigation.
• Larger studies and patient registries are needed to confirm these findings and establish optimal treatment protocols.